"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report)’s share price was down 4.6% on Thursday after UBS Group lowered their price target on the stock from $30.00 to $27.00. UBS Group ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...